Fuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big biopharma companies, and Amgen is no exception. The US biotech has just agreed a $2.7 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback